DMTX invaScan™, a novel and accurate tool for the diagnosis and prognosis of invasive tumors


DMTX invaScan is an immunohistochemistry assay, based on a monoclonal antibody that specifically detects collagen XI-α1 in tissue biopsy samples from patients with infiltrating carcinomas.

Technical benefits

  • Oncomatryx has developed a monoclonal antibody that is highly specific for human proCOL11A1. It does not cross-react with other similar collagens such as COL5A1 and it clearly marks peritumoral stromal cells.
  •  DMTX invaScan specifically detects COL11A1 in different tissue samples, with high sensitivity, specificity and reproducibility. A very clear intense intracellular staining of peritumoral fibroblasts, allows an easy interpretation of results, with no need for quantitation of the stain, nor complicated analysis of the morphological features of the positive cells. DMTX invaScan is optimized for its use in the common immunohistochemistry automated platforms in Pathology labs, allowing an user-friendly introduction in clinical routine.
  • The expression of COL11A1 in peritumoral stromal fibroblasts instead of tumor cells, enables the diagnosis of different types of tumors. Multicenter clinical validations in Europe and USA have already proven its clinical usefulness for breast, ovary, pancreas, head and neck, bladder and colon cancer.

Clinical benefits

  • DMTX invaScan facilitates diagnosis and prognosis of tumor invasiveness in small biopsy samples, aiding the selection of the most suitable treatment for each patient.

Clinical indications

DMTX InvaScan facilitates diagnosis and prognosis of different invasive carcinomas:

PANCREATIC CANCER: COL11A1 was found in the desmoplastic stroma of pancreatic ductal adenocarcinomas, distinguishing them from chronic pancreatitis and ampullary carcinomas (García-Pravia et al. 2013. PloS ONE 8(10): 1-13).

COLON CANCER: COL11A1 was detected in the stroma of colonic polyps with malignant component, distinguishing them from benign polyps (Galván JA. et al. BMC Cancer 2014; 14:867).

BREAST CANCER: COL11A1 was found in the desmoplastic stroma of infiltrating carcinomas, distinguishing them from benign inflamatory and sclerosing complex lesions. DMTX invaScan facilitates diagnosis of infiltrating breast tumors in biopsy core samples with high sensitivity and specificity (Fuentes-Martínez N. et al. Histol Histopathol. 2015; 30(1):87-93).

DMTX invaScan has shown higher sensitivity than myoepithelial markers (p63 and calponin) in detecting tumor invasion in core needle biopsies, diagnosing 25/25 infiltrating tumors that were misdiagnosed by current biomarkers (Freire et al. 2014. Pathol Res Pract. 2014; 210(12): 879-884).

BREAST PAPILLOMAS: Prognosis of recurrence and malignant recurrence of breast non-malignant papillary lesions. It has been validated by means of IHC on core needle biopsies of breast intraductal papillomas that were excised and followed up for longer than 5 years (Freire J. et al. BioMed Research International 2015; In Press).

HEAD AND NECK CANCER: COL11A1 was found in the desmoplastic stroma of squamous carcinomas in any localization, distinguishing them from benign lesions such as fibrosis, inflammation, leucocheratosis, ulcer, hyperplasia, etc.

KIDNEY CANCER: Collagen XI-α-1 was detected in the desmoplastic stroma of kidney carcinomas, distinguishing them from oncocytomas.

LUNG CANCER: Collagen XI-α-1 was detected in the desmoplastic stroma of lepidic-pattern adenocarcinomas, which makes the differentiation of in situ adenocarcinomas from pulmonary fibrosis possible.

OVARIAN CANCER: COL11A1 was detected in malignant ovarian tumors, distinguishing them from benign tumors and non-malignant lesions. Collagen-XI-α1 is also useful for the assessment of the invasiveness of borderline tumor implants. Increasing COL11A1 expression has been correlated with tumor invasiveness, metastasis and recurrence (Cheon, DJ. et al. Clin Cancer Res. 2014; 20(3):711-723).

BLADDER CANCER: COL11A1 was detected in the stroma of invasive bladder carcinomas (pT2), distinguishing them from superficial tumors and benign lesions (Freire et al. 2014. Pathology Journal of the RCPA. 46:S135).

Other published studies

COL11A1 has also been described as a useful biomarker for the diagnosis, prognosis and drug resistance prediction of many different tumor types:

OVARIAN CANCER: COL11A1 expression has been associated to drug resistance (Navabi, S. et al; BMC Genomics, 2016; 17(1):638; Teng, P.N. et al; Br J Cancer, 2014; 110(1):123-132) and bad prognosis (Tothill, R. W. et al; Clin Can Res, 2008; 14:5198-5208).

LUNG CANCER: COL11A1 has been related to bad prognosis (Chong, I.W. et al; Oncol Rep, 2006; 16(5):981-988) and drug resistance (Shen, L. et al; Oncol Rep, 2016; 36(2):877-885).

BREAST CANCER: COL11A1 expression in breast cancer patients has been associated to drug resistance (Farmer, P. et al; Nat Med, 2009; 15(1)68-74).

HEAD AND NECK CANCER: COL11A1 was found to be specifically expressed in metastasic oral/pharynx squamous cell carcinomas, distinguishing them from non-metastasic ones (Schmalbach, C. E. et al; Arch Otolaryngol Head Neck Surg, 2004; 130(3): 295-302). COL11A1 was also associated to tumor proliferation and invasion (Sok, j. C. et al; Br J Cancer, 2013; 109(12):3049-3056).

KIDNEY CANCER: COL11A1 expression in renal tumors has been associated to poor survival (Boguslawska, J. et al; J Urol, 2016; 195(6)1892-1902).

STOMACH CANCER: COL11A1 has been described as a good biomarker for distinguishing premalignant lesions from malignant tumors in the stomach (Zhao, Y. et al; Anat Rec (Hoboken), 2009; 292(5):692-700).

GLIOMA: COL11A1 was overexpressed in glioma tissues (An, J. H. et al; J Proteome Res, 2009; 8(6): 2873-2881).


Collagen type XI alpha 1: An accurate biomarker to predict malignant relapse of breast intraductal papillomas COL11A1 predicts malignancy in intraductal papilloma. Freire, J. et al. Biomed Res. Int.2015. 2015:812027

COL11A1/(pro)collagen 11A1 expression is a remarkable biomarker of human invasive carcinoma-associated stromal cells and carcinoma progression. Vázquez-Villa F. et al. Tumor Biology 2015; 36(4):2213-22

Overexpression of proCOL11A1 as a stromal marker of breast cancer. Fuentes-Martínez N. et al. Histol Histopathol. 2015; 30(1):87-93

Validation of COL11A1/procollagen 11A1 expression in TGF-β1-activated immortalised human mesenchymal cells and in stromal cells of human colon adenocarcinoma. Galván JA. et al. BMC Cancer 2014; 14:867

Overexpression of COL11A1 Aids in the Diagnosis of Invasive Carcinoma in Endoscopically Removed Malignant Colorectal Polyps. Zhang,D. et al. 2016. Pathol Res Pract 212(6):545-8

Collagen, type XI, alpha 1: an accurate marker for differential diagnosis of breast carcinoma invasiveness in core needle biopsies. Freire J. et al. Pathology Research and Practice 2014; 210(12): 879-884

A collagen-remodeling gene signature regulated by TGF-β signaling is associated with metastasis and poor survival in serous ovarian cancer. Cheon DJ. et al. Clinical Cancer Research 2014; 20(3):711-23

Overexpression of COL11A1 by Cancer-Associated Fibroblasts: Clinical Relevance of a Stromal Marker in Pancreatic Cancer. García-Pravia C. et al. PLoS ONE 2013; 8(10)1-13

Characterization of a novel mouse monoclonal antibody, clone 1E8.33, highly specific for human procollagen 11A1, a tumor-associated stromal component. García-Ocaña M. et al. International Journal of Oncology 2012; 40(5):1447-1454

Identifying candidate drivers of drug response in heterogeneous cancer by mining high throughput genomics data. Navabi, S. et al; BMC Genomics, 2016; 17(1):638; Teng, P.N. et al; Br J Cancer, 2014; 110(1):123-132

Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Tothill, R. W. et al; Clin Can Res, 2008; 14:5198-5208

Great potential of a panel of multiple hMTH1, SPD, ITGA11 and COL11A1 markers for diagnosis of patients with non-small cell lung cancer. Chong, I.W. et al; Oncol Rep, 2006; 16(5):981-988

COL11A1 is overexpressed in recurrent non-small cell lung cancer and promotes cell proliferation, migration, invasion and drug resistance. Shen, L. et al; Oncol Rep, 2016; 36(2):877-885

A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer. Farmer, P. et al; Nat Med, 2009; 15(1)68-74

Molecular profiling and the identification of genes associated with metastatic oral cavity/pharynx squamous cell carcinoma. Schmalbach, C. E. et al; Arch Otolaryngol Head Neck Surg, 2004; 130(3): 295-302

Collagen type XI α1 facilitates head and neck squamous cell cancer growth and invasion Sok, j. C. et al; Br J Cancer, 2013; 109(12):3049-3056

Expression of Genes Involved in Cellular Adhesion and Extracellular Matrix Remodeling Correlates with Poor Survival of Patients with Renal Cancer. Boguslawska, J. et al; J Urol, 2016; 195(6)1892-1902

A potential role of collagens expression in distinguishing between premalignant and malignant lesions in stomach. Zhao, Y. et al; Anat Rec (Hoboken), 2009; 292(5):692-700

Identification of gliotropic factors that induce human stem cell migration to malignant tumor. An, J. H. et al; J Proteome Res, 2009; 8(6): 2873-2881

ANY DIAGNOSTICS REQUEST? Make your question about Oncomatryx stroma-focused invasive tumors diagnostics platform

Please, fill this form

Your Diagnostics Request

Name (required)

Email (required)


By continuing to use the site, you agree to the use of cookies. Continue, scroll or accept. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.